News
Trial results, approvals, pricing changes, safety findings and market moves across peptides and GLP-1 medications — each traced to a primary source, each dated. For enforcement actions specifically, see the regulatory tracker.
- Trial results
- Approvals
- Pricing changes
- Safety findings
-
A third dual GLP-1/GIP drug reached 18% weight loss in a 120-person trial
Read more: A third dual GLP-1/GIP drug reached 18% weight loss in a 120-person trialA dual GLP-1/GIP receptor agonist made by a Chinese biotech produced up to 18.3% weight loss over 24 weeks in a placebo-controlled phase 2 trial, according to results published on 17 September in Diabetes, Obesity and Metabolism. The drug, BGM0504, acts on the same two gut-hormone receptors as tirzepatide. The trial was small, at 120…
-
Semaglutide’s heart benefit held across frailty levels in 17,604 SELECT patients
Read more: Semaglutide’s heart benefit held across frailty levels in 17,604 SELECT patientsOne of the open questions about GLP-1 drugs is whether they are a good idea in people who are already frail — older, carrying several conditions, less able to absorb a period of appetite loss. A new analysis of the SELECT trial, published in JAMA Cardiology on 16 September 2026, sorted all 17,604 participants by…
-
A berberine combination beat placebo in 93 adults, with three big caveats
Read more: A berberine combination beat placebo in 93 adults, with three big caveatsBerberine is sold online as a natural alternative to prescription weight-loss drugs, usually on evidence far thinner than the marketing. A randomised, double-blind, placebo-controlled trial published in Nutrients tested a fixed combination of berberine, white mulberry leaf extract and chromium picolinate in 93 Greek adults with obesity over 12 weeks, and found real differences against…
-
1 in 71 people on a GLP-1 drug aspirated or regurgitated under anaesthesia
Read more: 1 in 71 people on a GLP-1 drug aspirated or regurgitated under anaesthesiaIf you take a GLP-1 drug and have an operation booked, this is the study to know about. Across 119 UK hospitals and 47,039 patients, regurgitation or stomach contents entering the lungs happened to about 1 in 71 people taking a GLP-1 drug, against about 1 in 802 of everyone else. The events clustered at…
-
Orforglipron beat oral semaglutide on blood sugar and weight over 52 weeks
Read more: Orforglipron beat oral semaglutide on blood sugar and weight over 52 weeksEli Lilly posted the full results of ACHIEVE-3 to ClinicalTrials.gov on 15 September 2026, and they are the first detailed head-to-head numbers between the two oral GLP-1 drugs. Over 52 weeks in 1,698 adults with type 2 diabetes, the higher dose of orforglipron lowered blood sugar further than the higher dose of oral semaglutide and…
-
Teens on GLP-1 drugs had fewer recorded suicide-related events in an 18,444-patient study
Read more: Teens on GLP-1 drugs had fewer recorded suicide-related events in an 18,444-patient studyAdolescents with obesity who started semaglutide, liraglutide or tirzepatide were less likely to have a recorded suicide-related event over up to three years than matched adolescents managed with lifestyle intervention, according to an electronic health records study published on 14 September in Diabetes, Obesity and Metabolism. It points away from psychiatric harm in the age…
-
Two weight-loss products were hiding sibutramine, a drug withdrawn in 2010
Read more: Two weight-loss products were hiding sibutramine, a drug withdrawn in 2010The FDA on 15 September 2026 told consumers not to buy or use two products sold for weight loss, LUZE Fit Intensity and Beauty 911, after its laboratory found sibutramine in both. Neither label lists it. Sibutramine was the active ingredient in Meridia, a prescription weight-loss drug whose approval the FDA withdrew in 2010 after…
-
Nine people reacted to compounded wellness vials shipped to their homes
Read more: Nine people reacted to compounded wellness vials shipped to their homesNine people reported fever, chills, chest pain or vomiting after receiving compounded injections that a Houston pharmacy has now recalled nationwide. Centric Compounding is pulling six lots of glutathione, Myer’s Cocktail and Tri-Immune Boost, injectables sold to support immunity, fatigue and general wellness, after the glutathione raw ingredient used to make them was found to…
-
An online fat burner was found to contain fluoxetine and DNP
Read more: An online fat burner was found to contain fluoxetine and DNPA weight-loss supplement sold directly to consumers online has been recalled nationwide after FDA laboratory testing found two undeclared drugs inside the same box. The daytime tablets of Lipofit Extreme Fat Burner 2.0 contained fluoxetine, a prescription antidepressant. The nighttime tablets contained 2,4-dinitrophenol, a substance the FDA describes as a pesticide, dye, wood preservative and…
-
A European obesity society says the drugs have outrun the care around them
Read more: A European obesity society says the drugs have outrun the care around themThe European Association for the Study of Obesity has published a position statement whose argument is not about whether incretin drugs work. It treats that as settled. The argument is that everything around the prescription has failed to keep pace: patient selection, monitoring, clinician training and access have all moved more slowly than the drugs,…